CA2548483A1 - Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux - Google Patents

Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux Download PDF

Info

Publication number
CA2548483A1
CA2548483A1 CA002548483A CA2548483A CA2548483A1 CA 2548483 A1 CA2548483 A1 CA 2548483A1 CA 002548483 A CA002548483 A CA 002548483A CA 2548483 A CA2548483 A CA 2548483A CA 2548483 A1 CA2548483 A1 CA 2548483A1
Authority
CA
Canada
Prior art keywords
leu
ala
amino acid
ser
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002548483A
Other languages
English (en)
Inventor
Uwe Fiebig
Mirco Schmolke
Joachim Denner
Reinhardt Kurth
Alexander Karlas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Robert Koch Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10339966A external-priority patent/DE10339966A1/de
Application filed by Individual filed Critical Individual
Publication of CA2548483A1 publication Critical patent/CA2548483A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002548483A 2003-08-26 2004-08-26 Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux Abandoned CA2548483A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10339966.6 2003-08-26
DE10339966A DE10339966A1 (de) 2003-08-26 2003-08-26 Induktion antiviraler neutralisierender Antikörper beim Menschen und beim Tier
US50069903P 2003-09-08 2003-09-08
US60/500,699 2003-09-08
PCT/DE2004/001897 WO2005021574A2 (fr) 2003-08-26 2004-08-26 Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux

Publications (1)

Publication Number Publication Date
CA2548483A1 true CA2548483A1 (fr) 2005-03-10

Family

ID=34276529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002548483A Abandoned CA2548483A1 (fr) 2003-08-26 2004-08-26 Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux

Country Status (3)

Country Link
EP (1) EP1660523A2 (fr)
CA (1) CA2548483A1 (fr)
WO (1) WO2005021574A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588960B2 (en) 2005-04-12 2020-03-17 Duke University Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754715A1 (fr) * 2005-08-19 2007-02-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Vaccin à base des anticorps neutralisant un virus
WO2007107597A2 (fr) * 2006-03-21 2007-09-27 Bundesrepublik Deutschland, Vertreten Durch Das Bundesministerium Für Gesundheit, Dieses Vertreten Durch Das Robert-Koch-Institut Construction immunogene et procede pour le traitement prophylactique ou therapeutique du sida
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
WO2015048635A1 (fr) 2013-09-27 2015-04-02 Duke University Liposomes conjugués à mper et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes
US5124255A (en) * 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
ATE355300T1 (de) * 1996-11-06 2006-03-15 Genentech Inc Gespannte, helixformende peptide und verfahren um sie herzustellen
WO2001016183A1 (fr) * 1999-08-30 2001-03-08 U.S. Army Medical Research Institute Of Infectious Diseases Anticorps monoclonaux et vaccins contre les epitopes de la glycoproteine du virus d'ebola
DE19957838C2 (de) * 1999-11-25 2002-11-21 Pette Heinrich Inst Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
WO2002079239A2 (fr) * 2001-01-31 2002-10-10 U.S. Army Medical Research Institute Of Infectious Diseases Glycoproteine de filovirus chimere
FR2832424B1 (fr) * 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588960B2 (en) 2005-04-12 2020-03-17 Duke University Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

Also Published As

Publication number Publication date
EP1660523A2 (fr) 2006-05-31
WO2005021574A2 (fr) 2005-03-10
WO2005021574A3 (fr) 2005-11-24

Similar Documents

Publication Publication Date Title
JPH09501933A (ja) 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化
US7479550B2 (en) Amyloid β gene vaccines
KR20150118131A (ko) 안정화된 사람 면역결핍 바이러스 (hiv) 외피 (env) 삼량체 백신 및 이의 사용 방법
JP2015502353A (ja) インフルエンザウイルスワクチンおよびその使用
PT1240186E (pt) Melhorias em respostas imunitárias ou relacionadas com respostas imunitárias ao hiv
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
SK287382B6 (sk) Očkovacia kompozícia
HU214439B (hu) Eljárás HIV-fertőzések kezelésére alkalmas monoklonális antitestek és peptidek, valamint ezeket tartalmazó gyógyászati készítmények és vakcinák előállítására
CN113769080B (zh) 多肽免疫偶联物及其应用
AU752725B2 (en) Attenuated vif DNA immunization cassettes for genetic vaccines
WO2020046982A1 (fr) Compositions et procédés pour prévenir et traiter une infection virale
Nardelli et al. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide.
JP2023522154A (ja) インフルエンザワクチン
CA2548483A1 (fr) Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux
RU2691302C1 (ru) Иммуногенная композиция на основе рекомбинантных псевдоаденовирусных частиц, а также на основе белковых антигенов и способ получения иммуногенной композиции
US12016844B2 (en) Mammary tumor virus suppression
ES2748864T3 (es) Proteínas ENV lentivíricas mutadas y su uso como fármacos
EP3993873A1 (fr) Suppression du virus de tumeur mammaire
JP2014512353A (ja) 抗ウイルス組成物
JP2010029217A (ja) Hiv特異的ctlを誘導し得るペプチド及び該ペプチドを含む抗aids予防・治療剤
WO2024061188A1 (fr) Vaccin multivalent contre le coronavirus et son utilisation
US20240092840A1 (en) Vaccine formulation comprising recombinant overlapping peptides and native proteins
EP4144752A1 (fr) Particules virales pour le traitement ou la prévention d'une infection par un virus coronaviride
DE10339966A1 (de) Induktion antiviraler neutralisierender Antikörper beim Menschen und beim Tier
JP2001505763A (ja) Hiv p―17ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法

Legal Events

Date Code Title Description
FZDE Dead